I don't know the specifics of these funding proposals, but on this basic concept of bringing all of these actors together to work to solve a common problem, yes, but with the caveat that we need to think through the framework from start to finish, all of the steps that need to be in place, from the point of discovery through to the subsequent clinical trials to the marketing and access and affordability provisions. We can think of these things and build them into that product development pathway, and I think it's entirely possible for public funders to capture all of these things.
We have good clinical trial lists in Canadian public institutions. We have health charities and patient groups that are willing to work with collaborative models, but we need to create the framework that allows that collaboration to happen, not just at these punctuated intervals, but through a long-term perspective. Drug development is a long-term endeavour. If we don't have funding mechanisms and pathways that have thought through this and are there to provide that funding and that process and collaboration in a sustainable way, then we end up with a very fragmented system.